Over 2 years, tralokinumab was well tolerated and maintained long-term control of AD signs and symptoms.
No takes yet. Share an insight, caveat, or question.
Blauvelt et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: